Encompass Health Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29261A1007
USD
95.66
1.3 (1.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Encompass Health Corp. stock-summary
stock-summary
Encompass Health Corp.
Pharmaceuticals & Biotechnology
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 36 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The Company manages its operations through segments, including inpatient rehabilitation, and home health and hospice. It is an owner and operator of inpatient rehabilitation hospitals. It provides specialized rehabilitative treatment on both an inpatient and outpatient basis. It offers its home health and hospice services through Encompass Home Health and Hospice business (Encompass). Encompass operates home health and hospice agencies in 30 states, with concentrations in the Southeast, Oklahoma, and Texas. As of December 31, 2018, the Company operated 130 inpatient rehabilitation hospitals.
Company Coordinates stock-summary
Company Details
9001 Liberty Pkwy , BIRMINGHAM AL : 35242-7509
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 134 Schemes (45.77%)

Foreign Institutions

Held by 208 Foreign Institutions (15.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Leo Higdon
Non-Executive Independent Chairman of the Board
Mr. Mark Tarr
President, Chief Executive Officer, Director
Mr. Gregory Carmichael
Independent Director
Mr. John Chidsey
Independent Director
Mr. Donald Correll
Independent Director
Ms. Yvonne Curl
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,478 Million
(Quarterly Results - Sep 2025)
Net Profit:
175 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,002 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.73%

stock-summary
Debt Equity

0.83

stock-summary
Return on Equity

30.33%

stock-summary
Price to Book

4.21